Evidence map›Paper›PMID 39345183›Full record

ArticleAntimicrobial agents and chemotherapy2024

Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.

Lourdes Encinas, Si-Yang Li, Joaquin Rullas-Trincado, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Adolfo Garcia-Perez, Jin Lee, Rubén González Del Río, Jaime De Mercado and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lourdes EncinasGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Si-Yang LiCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Joaquin Rullas-TrincadoGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Rokeya TasneenCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Sandeep TyagiCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Heena SoniCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Adolfo Garcia-PerezDiscovery DMPK, GSK, Tres Cantos, Madrid, Spain.
Jin LeeCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Rubén González Del RíoGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Jaime De MercadoDiscovery DMPK, GSK, Tres Cantos, Madrid, Spain.
Verónica SousaCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Izidor SosičFaculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Stanislav GobecFaculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Alfonso Mendoza-LosanaGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Paul J ConverseCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-1256-7464
Khisi MdluliTB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
Nader FotouhiTB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
David Barros-AguirreGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0002-4099-0438
Eric L NuermbergerCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-1440-9889

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoniazid is an important first-line medicine to treat tuberculosis (TB). Isoniazid resistance increases the risk of poor treatment outcomes and development of multidrug resistance, and is driven primarily by mutations involving

Indexed as

Antitubercular AgentsBacterial ProteinsDisease Models, AnimalIsoniazidMycobacterium tuberculosisOxidoreductasesAnimalsFemaleMiceMicrobial Sensitivity TestsTuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial ProteinsInhA protein, MycobacteriumIsoniazidOxidoreductasesGSK138GSK2505693AGSK3081138AGSK693InhA inhibitormousetuberculosistuberculosis drugs

Identifiers

PMID39345183
PMCPMC11539229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.